Terry-Ann Burrell, Director at RECURSION PHARMACEUTICALS, INC. (RXRX), sold 227,648 shares at $12.59 ($2.7M) on 2023-07-13, disclosed to the SEC on 2023-07-14.
Open-market sale of $2.7M RXRX by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $11.25 | 24,302 | $273K | 10.0% |
| 2 | $11.25 | 24,302 | $273K | 10.0% |
| 3 | $12.15 | 78,071 | $949K | 34.6% |
| 4 | $12.15 | 78,071 | $949K | 34.6% |
| 5 | $13.18 | 3,195 | $42K | 1.5% |
| 6 | $14.08 | 3,157 |
| $44K |
| 1.6% |
| 7 | $12.59 | 8,275 | $104K | 3.8% |
| 8 | $12.59 | 8,275 | $104K | 3.8% |
| Total | $12.03 avg | 227,648 | $2.7M | 100% |
| Filing → |
| BEAM | SELL | 2023-01-30 | $3.3M | — | Filing → |
| BEAM | SELL | 2023-01-25 | $1.8M | — | Filing → |
| BEAM | SELL | 2023-01-20 | $4.3M | — | Filing → |